Attached files

file filename
EX-32.1 - EX-32.1 - Nabriva Therapeutics plca17-11553_1ex32d1.htm
EX-31.2 - EX-31.2 - Nabriva Therapeutics plca17-11553_1ex31d2.htm
EX-31.1 - EX-31.1 - Nabriva Therapeutics plca17-11553_1ex31d1.htm
10-Q - 10-Q - Nabriva Therapeutics plca17-11553_110q.htm

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Nabriva Therapeutics AG (the “Company”) for the period ended March 31, 2017 as filed with  as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Gary Sender, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:

 

(1)                                 the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)                                 the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ Gary Sender

 

 

 

Gary Sender

 

Chief Financial Officer

 

(Principal Financial Officer)

 

 

 

Dated: May 10, 2017